TABLE 3.

Flow cytometric analysis of selected T-cell surface markers (after minus before) after anti-CTLA-4 and IL-2 treatment in selected patients

Patient no.	HLA-DR+ (CD3+CD4+)	HLA-DR+ (CD3+CD4−)	CD45RO+ (CD3+CD4+)	CD45RO+ (CD3+CD4−)	CD69+ (CD3+CD4+)	CD69+ (CD3+ CD4−)	CD25+ (CD4+)
4a	7.3%	7.2%	7.4%	5.5%	5.2%	7.5%	7.9%
5	−15.4%	−26.7%	2.8%	−1.0%	−14.3%	−5.1%	−5.1%
6	11.4%	−5.6%	1.8%	6.3%	34.2%	27.9%	12.7%
8a	12.1%	5.1%	4.4%	5.9%	7.8%	7.0%	5.0%
9	7.5%	11.1%	−.7%	−15.2%	41.1%	39.1%	10.1%
10	11.1%	11.5%	.9%	−5.9%	−2.4%	−9.4%	.9%
11	−6.3%	6.3%	−11.7%	−5.5%	−9.4%	−7.6%	−1.1%
12a	9.8%	11.9%	10.7%	−19.7%	−18.7%	−10.3%	14.6%
13	7.4%	9.8%	17.5%	−2.2%	.9%	−2.8%	18.4%
14a	28.1%	13.0%	2.3%	1.4%	−11.4%	1.1%	.8%
15a	13.6%	16.4%	4.8%	2.1%	−9.6%	−10.1%	16.3%
16	8.2%	7.9%	2.4%	−1.1%	8.9%	−2.5%	1.1%
17	5.9%	−2.5%	1.4%	−.2%	13.1%	14.9%	1.6%
18	7.3%	15.8%	9.3%	−1.3%	1.3%	2.6%	6.4%
19a	−6.5%	−16.2%	6.2%	−9.5%	−30.2%	−10.2%	−.3%
20a	−.1%	15.3%	.2%	−17.5%	−48.0%	−33.8%	−2.4%
22	4.7%	12.5%	−3.0%	−4.3%	2.7%	2.8%	−4.6%
23	−1.1%	10.1%	3.6%	7.9%	.1%	.8%	1.2%
24	11.8%	15.0%	2.0%	16.1%	.3%	2.5%	4.8%
25	10.3%	7.3%	−.7%	2.3%	1.0%	11.9%	11.4%
26	−2.0%	−3.7%	11.5%	2.6%	14.4%	8.5%	7.5%
27	11.0%	10.9%	1.4%	−2.3%	−6.6%	−7.3%	5.6%
28a	21.2%	24.5%	8.3%	−2.6%	12.2%	−2.2%	6.6%
29	8.6%	17.1%	11.3%	21.4%	−.2%	2.5%	1.0%
30	1.0%	1.5%	3.5%	−5.3%	0.5%	3.9%	2.3%
32	13.4%	28.1%	6.5%	8.1%	21.6%	16.8%	−3.4%
34	10.1%	7.0%	4.8%	−6.3%	3.2%	2.6%	−5.8%
35	1.4%	−11.0%	7.5%	1.1%	−2.2%	−4.8%	−3.7%
Mean change	6.9%	7.1%	4.2%	−.7%	.6%	1.7%	3.9%
P valueb	.0003	.0033	.0004	.6871	.8672	.5184	.0041

CTLA, cytotoxic T-lymphocyte–associated antigen; IL, interleukin.

^aObjective clinical responders.

^bTwo-tailed P value using the paired t-test.